ITGAX and neoplasm: As demonstrated in Figure 7A, percentages of CD11c+ cells in the blood were increased in tumor-bearing mice, including B16-injected FVB/N and C57BL/6 mice and LLC-injected FVB/N and C57BL/6 mice.